Abstract
To the Editor: In the case series presented by Müller et al. (Feb. 22 issue),1 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy in patients with systemic lupus erythematosus (SLE) resulted in prompt clinical and serologic remission. In contrast, in patients with Scl70+ systemic sclerosis, serologic remission after CAR T-cell therapy was not as complete. This observation is discrepant with the case of a patient with systemic sclerosis that we recently presented.2 In the case series, CAR T cells disappeared within a few weeks, whereas the third-generation CD19 CAR T cells that we administered were still detectable at 11 months. It .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
